News | Mammography | April 12, 2024

The latest MyBreastAI Suite supports clinicians in accelerating breast cancer detection, while the company’s Pristina Bright solution helps healthcare providers start a new contrast program

The latest MyBreastAI Suite supports clinicians in accelerating breast cancer detection, while the company’s Pristina Bright solution helps healthcare providers start a new contrast program

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast cancer detection technology during the 2024 Society of Breast Imaging Symposium in Montreal, Canada, April 11-14, 2024. This year’s showcase will feature the Mobile Mammography Screening Truck, the recently released MyBreastAI Suite* and Pristina Bright** offering to demonstrate the company’s personalized approach to transforming breast cancer imaging.

Breast cancer is the most commonly diagnosed cancer among women, with one in eight facing diagnosis in their lifetime.1 Regular mammograms are critical, but their effectiveness is reduced in women with dense breast tissue, who are four to six times more likely to develop breast cancer.2 As a result, clinicians are turning to supplemental screening options and artificial intelligence (AI) technologies to help enhance the detection and diagnosis of breast cancer, improve patient outcomes, and help with radiology workflow so more patients can benefit from the world’s most sophisticated mammography tools.3

GE HealthCare’s latest MyBreastAI Suite provides an all-in-one AI platform optimized for mammography to support clinicians with breast cancer detection. With this initial release, MyBreastAI Suite integrates three AI applications from iCAD including ProFound AI for DBT, SecondLook for 2D Mammography and PowerLook Density Assessment to help support early detection and improve patient outcomes, as well as help radiology departments improve operational productivity.

"As part of GE HealthCare’s ongoing commitment to transform healthcare and improve patient outcomes, we continue to explore how we can leverage the power of AI in mammography to support the early detection of breast cancer,” says Pooja Pathak – Vice President and General Manager of Mammography. “We look forward to sharing this latest tool in our portfolio of technologies for personalized breast cancer care with the breast imaging community this year at SBI2024.”

Contrast-Enhanced Mammography (CEM), a technology first pioneered by GE HealthCare in 2010, is a game changer in breast diagnostic imaging and biopsy care - with over 200 publications that demonstrate its clinical performances.

In an effort to help further advance breast cancer and support healthcare providers in starting a new contrast program, the company will also be showcasing its Pristina Bright offering - a comprehensive solution that combines SenoBright HD, Pristina Serena, and Serena Bright with an education program that includes dedicated on-site support, CME accredited self-assessment, and access to a users’ club to share with experts around the globe and leverage resources needed to market their facility among referring doctors and patients.

With Pristina Bright, clinicians can see lesions that cannot be seen on routine mammography4 5 6 and biopsy what is seen within 15 minutes.7 To help improve overall productivity, Pristina Bright can also help providers take more patients on their system, with the ability to image up to 30 patients a day with contrast mammography8 through an easy-to-read exam.

“Through our research and clinical experiences, contrast enhanced mammography (CEM) continues to emerge as game-changer in helping to improve breast cancer outcomes for patients facing this difficult diagnosis,” shares Dr. Jordana Phillips – Radiologist at Boston Medical Center. “When it comes to findings that are difficult to define, CEM leverages the addition of a contrast agent to highlight unusual areas of blood flow - providing an efficient yet familiar, patient-centric approach to evaluate the presence of cancer with high sensitivity and specificity. With contrast, we’re able to turn a normal mammogram into something that provides so much more information which accelerates our ability to make a confident diagnosis. We’re excited to be joining GE HealthCare and the breast imaging community at SBI 2024 to share more about our experience through the hands-on learning course, as well as share how we’ve implemented CEM as part of our efforts to provide personalized breast cancer care to community we serve.”

As part of the company’s commitment to enabling access to healthcare, GE HealthCare will have its mobile mammography showcase onsite. Attendees will have the unique opportunity to explore the capabilities of this unit designed to offer convenient screening set-up within the familiar environment of a workplace. The truck is equipped with the Senographe Pristina and Invenia ABUS to ensure accurate and efficient screenings.

Visit booth 301 to learn more about GE HealthCare’s personalized breast cancer screening solutions, including:

  • Senographe Pristina, a mammography system designed to provide a better patient experience and optimized for rapid diagnosis;
  • Invenia ABUS, the first FDA-approved automatic breast ultrasound supplemental screening specifically designed for detecting cancer in dense breast;
  • SenoBright HD Contrast Enhanced Mammography (CEM), which combines mammography and vascular-based screening methods to highlight areas of unusual blood-flow patterns that may indicate malignancy - helping reduce the masking effect of fibro glandular breast tissue so lesions can be more clearly identifiable; and
  • Serena Bright, the industry’s first contrast-guided biopsy solution which transforms the screening room into an interventional suite if medical indications recommend pathology.

For more information: www.gehealthcare.com

Find more SBI24 conference coverage here

 

References:

*MyBreastAI suite is a commercial offering that includes GE HealthCare’s Edison Health Services platform, ProFound AI for DBT, SecondLook for 2D Mammography and PowerLook Density Assessment. These applications are provided by iCAD. MyBreastAI Suite is compatible with the latest versions of iCAD, Inc. as of November 14, 2023.

 

** Pristina Bright is a commercial offering including SenoBright HD, Pristina Serena and Serena Bright.


Related Content

News | Radiology Business

May 20, 2024 — Associated Medical Professionals of NY (A.M.P.) announced that internationally recognized radiation ...

Time May 20, 2024
arrow
News | ASTRO

May 17, 2024 — Registration opens today for the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting ...

Time May 17, 2024
arrow
News | Radiation Therapy

May 16, 2024 — Today marks a significant milestone in cancer care with the introduction of bipartisan federal ...

Time May 16, 2024
arrow
Sponsored Content | Case Study | Enterprise Imaging

Having the most efficient clinical workflows with enhanced diagnostic capabilities is a major goal for clinicians and ...

Time May 16, 2024
arrow
News | Artificial Intelligence

May 15, 2024 — Heart disease is the leading cause of mortality in the U.S., accounting for one out of every five deaths ...

Time May 15, 2024
arrow
News | Pediatric Imaging

May 15, 2024 — Transfer learning (TL) models trained on heterogeneous public datasets and fine-tuned using institutional ...

Time May 15, 2024
arrow
News | FDA

May 14, 2024 — Indica Labs, the leading provider of digital pathology solutions, announced today that it received FDA ...

Time May 14, 2024
arrow
News | Radiology Business

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
arrow
News | Artificial Intelligence

May 14, 2024 — Elekta announced the launch of its latest linear accelerator (linac), Evo*, a CT-Linac with new high ...

Time May 14, 2024
arrow
News | Prostate Cancer

May 13, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils ...

Time May 13, 2024
arrow
Subscribe Now